Cargando…
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in youn...
Autores principales: | Kang, Zhigang, Sun, Shi-Yong, Cao, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345273/ https://www.ncbi.nlm.nih.gov/pubmed/22577581 http://dx.doi.org/10.5402/2012/395952 |
Ejemplares similares
-
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
por: Fulda, Simone
Publicado: (2012) -
Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011) -
Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma
por: Pomella, Silvia, et al.
Publicado: (2022) -
Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications
por: PONIEWIERSKA-BARAN, AGATA, et al.
Publicado: (2015) -
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies
por: Zarrabi, Ali, et al.
Publicado: (2023)